<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468169</url>
  </required_header>
  <id_info>
    <org_study_id>14401A</org_study_id>
    <nct_id>NCT00468169</nct_id>
  </id_info>
  <brief_title>Cetuximab (ERBITUX速) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer</brief_title>
  <acronym>EPIC</acronym>
  <official_title>A Randomized Phase II Trial of Concurrent Chemoradiation With Cetuximab (ERBITUX速), 5 Fluorouracil, Hydroxyurea, and Twice-daily Radiation (CetuxFHX) Versus Cetuximab (ERBITUX速), Cisplatin, and Accelerated Radiation With Concomitant Boost (CetuxPX) After Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to explore and compare the efficacy of Cetuximab (ERBITUX速)
      added to two concurrent chemoradiotherapy platforms of different intensity in locally
      advanced head and neck cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS) and overall survival (OS)</measure>
    <time_frame>1-year and 2-year progression free survival as well as overall survival</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess and compare the toxicity profile of both regimens; to assess best overall response rate</measure>
    <time_frame>1 and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The chemotherapy with radiation will consist of a combination of two drugs, cisplatin and cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The chemotherapy with radiation will consist of 5-FU, hydroxyurea and cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab - Arm A:250mg/m2(day 1, weekly x 10); Cetuximab - Arm B:250mg/m2(day 1, weekly x 7)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Stage III and IV head and neck cancer

          -  Patients with squamous cell carcinoma of unknown primary and suspected origin in the
             head and neck area

          -  No prior chemotherapy or radiotherapy

          -  Prior surgical therapy of incisional or excisional biopsy and organ-sparing procedures
             only

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

          -  Normal organ and marrow function

        Exclusion Criteria:

          -  Unequivocal demonstration of metastatic disease

          -  Known severe hypersensitivity to drugs used in the study

          -  Treatment with a non-approved or investigational drug within 30 days before Day 1

          -  Incomplete healing from previous surgery

          -  Pregnancy or breast feeding

          -  Uncontrolled intercurrent illness including

          -  Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any
             history of clinically significant CHF

          -  Acute hepatitis or known HIV

          -  Severe baseline neurologic deficits

          -  Prior therapy which specifically and directly targets the EGFR pathway

          -  Prior severe infusion reaction to a monoclonal antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everett E Vokes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2007</study_first_posted>
  <last_update_submitted>October 5, 2012</last_update_submitted>
  <last_update_submitted_qc>October 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chicago</investigator_affiliation>
    <investigator_full_name>Everett Vokes</investigator_full_name>
    <investigator_title>Chairman, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cetuximab</keyword>
  <keyword>Erbitux</keyword>
  <keyword>locally</keyword>
  <keyword>advanced</keyword>
  <keyword>head</keyword>
  <keyword>neck</keyword>
  <keyword>cancer</keyword>
  <keyword>neoplasms</keyword>
  <keyword>squamous</keyword>
  <keyword>carcinoma</keyword>
  <keyword>lymphoepithelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

